Colinz Laboratories Limited (BOM:531210)

Market Cap	102.23M
Revenue (ttm)	63.47M
Net Income (ttm)	4.79M
Shares Out	2.52M
EPS (ttm)	1.90
PE Ratio	21.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,032
Average Volume	352
Open	42.04
Previous Close	42.04
Day's Range	41.20 - 42.04
52-Week Range	37.87 - 88.70
Beta	0.30
RSI	30.08
Earnings Date	Jul 30, 2025

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, and creams, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, and pegylated liposome doxorubicin, etc.; antiritr...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 69
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531210

Financial Performance

In 2024, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.